IW 1973

Drug Profile

IW 1973

Alternative Names: IW1973; sGC agonist-Ironwood

Latest Information Update: 02 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Cardiovascular therapies
  • Mechanism of Action Soluble guanylyl cyclase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Hypertension in diabetes
  • Phase I Pulmonary arterial hypertension

Most Recent Events

  • 16 Aug 2017 Ironwood Pharmaceuticals plans the phase II CAPACITY-HFpEF trial for Heart failure (In adults, In the elderly) (PO) (NCT03254485)
  • 09 Jun 2017 Pharmacodynamics data from a preclinical trial in Hypertension in diabetes presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 01 Apr 2017 Ironwood Pharmaceuticals completes a phase II trial in Cardiovascular disorders in USA (PO) (NCT02906579)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top